Intravascular Ultrasound Systems Market Poised for Steady Growth in the Future

Intravascular Ultrasound Systems (IVUS) is an imaging method with which we can visualize a coronary artery from the inside out. Intravascular Ultrasound Systems are usually designed in such a way that the individual can have a complete view of the coronary artery blockade using a catheter which is attached to an ultrasound probe at one end and the other end is attached to a computerized ultrasound equipment.

The inside out view helps to find out the sent sizing, fixation, and in confirmation that the stent implanted are appropriately placed with full expansion of the stent, which fits tightly round around vessel wall. By this the cardiologist sense that the information acquired by the IVUS medium can a make a huge different in knowing how well the patients are treated and can obtain accuracy about the stent placement with reduced complications.

Now a days the IVUS diagnostic procedure is majorly used in coronary interventions where it determines and provides the qualitative information about the composition of the plaques and its echogenicity strategies. IVUS demonstrates the consistency of the plaque (soft, fibrous, calcific or mixed) and its differentiation from thrombus.

IVUS instrumentation overview:

The Intravascular Ultrasound is designed with two major components i.e.

  • Catheter with a miniaturized transducer at its tip
  • Console containing the electronics necessary to reconstruct the image

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1858

The imagining is captured by the frequency of the ultrasound which varies type of vessels which is to be scanned.

  • Often used frequency is 20 MHz
  • Vascular imagining for a medium sized vessel is 12.5 – 50 MHz
  • Vascular imagining for a large vessel such a aorta is 12.5 – 20 MHz
  • Smaller vessels require high frequency of probes within a range of 30-40 MHz

Two types of catheter systems are, one with an end-hole which are delivered over the guide wire, and those which do not have an end-hole and are introduced directly through the sheath.

The transducer design have been approached into two basic ways, i.e.

  • Phased-array
  • Mechanical type

In the phased-array systems, there are multiple transducer elements (32-64) which are in arranged in an array are activated sequentially to generate the image.

Mechanical probes rotates an electric transducer at 1800 rpm, which has the capacity to produce 30 images per second.

Intravascular Ultrasound Systems Market: Drivers and Restraints

There is drastic Increase in the number percutaneous coronary interventions and number of stent procedures. Major Lot of population now a days prefer less invasive procedures, the technological advancements in image guided therapeutic treatment and growing incidence of cardiovascular disease led to the increase in the intravascular ultrasound systems market.

The drawback for the IVUS is the high cost, lack of uniform reimbursement and threat from optical coherence tomography.

Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1858

Intravascular Ultrasound Systems Market: Segmentation        

The global market for intravascular ultrasound systems are broadly classified on the basis of product type, applications and end user.

Based on product type, the intravascular ultrasound systems market has been segmented as follows:

  • IVUS consoles
    • Integrated Consoles
    • Cart version Consoles
  • IVUS catheters
    • Mechanical/Rotatory Catheters
    • Static Electric/ Phased Array Catheters
  • Accessories
    • Pullback devices
    • Guide wires
    • Introducer Sheaths

Based on application type, the intravascular ultrasound systems market has been segmented as follows:

  • IVUS coronary diagnostic market
  • IVUS coronary intervention market
  • IVUS coronary research market
  • IVUS non-coronary /peripheral applications market

 Based on end user, theintravascular ultrasound systems market has been segmented as follows:

  • Hospitals
  • Cancer Institute

Intravascular Ultrasound Systems Market: Overview

The global Intravascular Ultrasound Systems market is expected to expand at healthy CAGR owing to increasing adoption of the products across the world. Among end users, hospital end user segment is expected to account for maximum share due to requirement of advanced healthcare infrastructure and low cost.

Full Report Analysis@ http://www.futuremarketinsights.com/reports/intravascular-ultrasound-systems-market

Intravascular Ultrasound Systems: Region-wise Outlook

Geographically, the global intravenous ultrasound systems market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. Among all the regions, North America will continue to lead the global market for intravenous ultrasound systems due to high purchasing power. Asia- Pacific is expected to account for second largest share in global market primarily due to increasing number of cardiac surgeries. Regional overview can be a directly proportional to the population.

Intravascular Ultrasound Systems: Key Players

Key players operating in the global intravenous ultrasound systems market are Volcano Corporation, Boston Scientific Corporation, Terumo Corporation, Infra ReDx Inc, Philips Healthcare, Siemens Healthcare, Silicon Valley Medical Instruments Inc, and Avinger Inc.

Advertisements

Market Research on Diabetes Care Devices Market 2014 and Analysis to 2020

Diabetes is a condition in which the body is unable to use the glucose which is the main source of energy for the body cells. There are two different type of diabetes, when the pancreases are unable to make enough insulin and the other is when the body is not responding to the insulin made. The people suffering from diabetes cannot obtain relief throughout their life.

The factors driving the growth of the market in the BRIC region are increasing population of diabetes, low diagnosis rate; initiative taken by the government and mainly due to dynamic participation from the companies. The market for diabetes care devices exhibits high growth potential as the saturation level for the devices are expected to be very low. Advancement and innovation in technologies will further boost the market growth.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-236

But the factors restraining the growth of the market differs in different region of BRIC. But some of the common barriers in the growth market are illiteracy about the use of devices, incomplete awareness about the disease and its problems, limitations by geography, long registration process of medical devices and development of alternative solutions. As the issues of settlement are common, the market in the BRIC region is expected to increase exponentially. Devices which are low in cost and comfortable in use will remain the most popular.

This research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data and statistically-supported and industry-validated market data and projections with a suitable set of assumptions and methodology.

Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-236

Western Europe has been Estimated to Dominate the Europe Viscosupplementation Market

Future Market Insights (FMI) delivers key insights on the Europe viscosupplementation market in its upcoming report titled, “Viscosupplementation Market: Europe Industry Analysis and Opportunity Assessment, 2016-2026”. In terms of revenue, the Europe viscosupplementation market is projected to register a healthy CAGR of 5.1% during 2016-2026.

FMI’s report has segmented the market on the basis of product type, end user and region.

Based on product type, the market has been segmented into one injection viscosupplementation, three injection viscosupplementation and five injection viscosupplementation.

Single injection viscosupplementation product type segment is expected to emerge as the most popular segment over the forecast period, driven by better patient compliance as the treatment reduces the need for multiple hospital visits. The segment is expected to register the highest CAGR of 6.7% during the forecast period.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-eu-1383

Five injection viscosupplementation product type segment is expected to witness a decline in market share in terms of revenue from 29.0% in 2015 to 23.3% in 2026. This decline is attributed to more incidence of side effects and repeated patient visit requirements associated with five injection viscosupplementation. Reimbursement cutbacks and high injection costs are other factors that can curtail demand for five injection viscosupplementation.

By end-users, the market is segmented into hospitals, ambulatory surgical centres and orthopaedic clinics. Hospitals end-use segment is expected to witness significant demand for viscosupplementation, registering a CAGR of 4.3% over the forecast period. Better reimbursement options and increasing patient preference for single injection cycle for osteoarthritis treatment is expected to drive demand for one injection viscosupplementation in the orthopaedic clinics segment over the forecast period.

Europe Viscosupplementation Market Trends

Key trends in the viscosupplementation market are the use of single injection cycle for osteoarthritis treatment and introduction of new combination products in the market. For example, the product pipeline of major players in the viscosupplementation market involves combining corticosteroid injections, which help in relieving pain associated with osteoarthritis, with long-lasting effects of hyaluronic acid, which lasts for nearly six months. Further, regional competition within EU countries, especially in five injection cycle, is leading to entry of new market players. Europe is a mature market in terms of generic products and it is therefore relatively easier to obtain CE mark in Europe than it is to obtain the U.S. FDA approval.

Speak To Analyst@ http://www.futuremarketinsights.com/askus/rep-eu-1383

Western Europe has been estimated to dominate the Europe viscosupplementation market in 2015, attributed to factors such as the presence of key regional players, strong distribution network and better healthcare infrastructure in the region.

Key Players in Europe Viscosupplementation Market

Some key players in the Europe viscosupplementation market are Anika Therapeutics Inc., Sanofi S.A., Zimmer Biomet Holdings, Meda AB, Ferring B.V, Fidia Pharmaceutici S.p.A,   and Bioventus LLC. We have discussed individual strategies followed by these companies in terms of enhancing product designs, creating new manufacturing facilities, market consolidation and advanced R&D initiatives. The report concludes with key takeaways that could help players already present in the market and new players planning to enter the market in the long run.

Browse the full “Viscosupplementation Market: Europe Industry Analysis and Opportunity Assessment, 2016 – 2026” market research report at http://www.futuremarketinsights.com/reports/europe-viscosupplementation-market

Teleradiology Market: North America will Remain the Largest Market through 2023

Global teleradiology market revenues are expected to reach a total of US$ 1,738.4 Mn in 2016, a year-over-year growth of 13%. The U.S. will continue to be at the forefront of global adoption, with high awareness and availability of advanced teleradiology software boosting growth of the market. Overall, the North America teleradiology market is anticipated to reach US$ 688.2 Mn in 2016.

In addition to North America, other key markets for teleradiology include the U.K. and Germany in Europe, and Australia, Malaysia, and Philippines in Asia Pacific. The Europe teleradiology market is expected to grow by 13.1% in terms of revenues in 2016, whereas the APAC radiology market’s growth is projected at 13.8%. U.K. and Australia will continue to remain the largest markets for teleradiology in Europe and APAC respectively.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1747

Rapid development in digital image processing technologies, and advancement in telecommunications, digital technology, and healthcare informatics are fuelling the adoption of radiology in these key markets. Lack of expert radiologists has also contributed to making teleradiology an appealing alternative in emergency cases for a second opinion. While these factors are expected to fuel the growth of the market in 2016 and beyond, high cost, combined with lack of foolproof security can pose challenges to adoption.

global teleradiology market

On the basis of modality, X-rays are the most commonly used imaging procedure in the teleradiology market. This segment was valued at US$ 449.1 Mn in 2015, and is anticipated to grow by 11.5% in 2016 to reach US$ 500.7 Mn in revenues. X-ray technique is highly economical and is widely used in primary diagnosis, becoming an integral part in both small and large healthcare providers. While X-rays will continue to the largest segment on the basis of modality, adoption of computed tomography (CT) scan is also witnessing robust growth. The CT scan segment is anticipated to witness a growth rate of 14.9% in 2016.

Speak To Analyst@ http://www.futuremarketinsights.com/askus/rep-gb-1747

Key players in the global teleradiology market include Everlight Radiology, InHealth, Global Diagnostics Ltd., Radisphere National Radiology Group, Inc., TeleDiagnosys Services Pvt Ltd., Telemedicine Clinic Cybernet Medical Corporation, Agfa-Gevaert N.V., Sectra AB, Medica Reporting Ltd., ONRAD, Inc., Radiology Reporting Online (RRO), RamSoft, Inc., Teleradiology Solutions, Inc., The Telelaudo, Virtual Radiologic and (vRad).

Long-term Outlook: The global teleradiology market is anticipated to increase at a CAGR of 11.2% during the forecast period 2015–2023. North America will remain the largest market during the end of the forecast period, whereas CT scan will pip X-rays to emerge as the largest segment on the basis of modality.

Full Report Analysis@ http://www.futuremarketinsights.com/reports/teleradiology-market

Industrial Microbiology Market: Reaction Consumables Segment is Expected to Dominate the Market

The global industrial microbiology market is expected to witness a y-o-y growth of 6.7% in 2016 over 2015 and reach US$ 9.46 Bn in revenues. North America will continue to be the most lucrative market, accounting for over 25% of the market share.

In addition to increase in food consumption, rising emphasis on industrial food safety is predicted to fuel market growth. Wide-ranging applications of industrial microbiology and biotechnology in various verticals, including agriculture, pharmaceuticals, and food & beverages are also expected to play a key role in driving the growth of the market. Consumer preference towards nutraceuticals, increasing automation, and strategic partnerships across the healthcare value chain are other key drivers for industrial microbiology market.

Manufacturing of sterile products specifically demands higher costs in order to maintain aseptic conditions, which remains an abiding challenge for the market. Growing demand for advanced technology is also expected to hamper market growth.

Apart from applications in fermentation of wine, beer, and cheese, the use of industrial microorganisms in syrup formulation is also gaining traction. Other influential trends include use in bioremediation processes, manufacturing of empty capsules, and preparation of genetically modified food products.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1743

On the basis of product type, the global industrial microbiology market is segmented into reaction consumables, equipment & systems, and laboratory supply. While the reaction consumables segment is expected to dominate the market with over 60% of the total market share in 2016, equipment and systems segment’s revenue share will be over 25%. By test type, sterility testing and microbial limit testing are projected to collectively contribute around 60% to the total market share.

The pharmaceuticals & biotechnology segment will remain the largest end-use segment in the industrial microbiology segment, owing to rising novel drug development practices.

America will remain the largest and fastest growing market due to easier product approval processes. The U.S., a leading market for pharmaceuticals, will continue to dominate the North American market, accounting for over three-fourths revenue shares in 2016. Europe will maintain its position as the second largest market for industrial microbiology.

Speak To Analyst@ http://www.futuremarketinsights.com/askus/rep-gb-1743

Thermo Fisher Scientific Inc., and bioMérieux SA remained the two largest players, accounting for a market share of 34.8% in 2015 (with respect to reaction consumables segment & reagent kits). Strong product portfolio, strategic R&D, strong market channels, prominent market presence, and sizeable presence in developing regions remain key strengths of these market leaders. Other leading players in the market include Merck KGaA, Qiagen, Sartorius AG, Bio-Rad Laboratories, Inc., and Becton, Dickinson and Company.

Long-term Outlook: The global industrial microbiology market is expected to expand at a CAGR of 7.1% over the forecast period, 2016-2024. FMI reports growing opportunities in the market, especially for pharmaceutical and biotechnology companies.

Platelet Rich Plasma (PRP) Market: Orthopaedic Surgery will be the Largest Application Segment

The global platelet rich plasma (PRP) market is projected to witness a year-over-year growth rate of 11.8% in 2016 over 2015 to reach US$ 224.0 Mn in revenues. Increase in the number of patients suffering from orthopaedic injuries and widening application area of PRP in different surgeries is likely to catalyse the market the growth. Use of PRP therapy in treating sports injuries is also anticipated to boost the growth of the market.

By type, pure PRP is likely to dominate product segment in 2016 with the revenue share of about 65%. The segment is also forecast to dominate other application segments through the forecast period. This segment is estimated to witness a year-over-year growth of 11.4% to reach US$ 144.3 Mn in revenues in 2016. Pure PRF/Leukocyte rich PRF segment is projected to register impressive year-over-year growth of 15.5% in 2016.

By origin, autologous segment will continue to be the prominent segment in 2016, accounting for three fourth of total revenue generated in the year. This segment will witness a year-over-year growth of 11.0% to reach US$ 169.1 Mn in revenues in 2016. Autologous segment among other PRP origins is slated to reflect moderate market performance in 2016, is likely to lose market share to allogenic PRP over next four to five years. Allogenic segment is also projected to register an impressive year-over-year growth of nearly 15% in 2016.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1722

Examining the PRP demand statistics from different surgeries clearly forebodes the dominance of orthopaedic surgery. Currently, orthopaedic surgery is the leading application segment accounting for a revenue share of over 35% in 2016.Orthopaedic surgery is followed by cosmetic surgery, which is estimated to be valued over US$ 50 Mn in 2016. Cosmetic surgery will continue to remain the second-largest application segment, with total revenues expected to reach US$ 59.6 Mn by 2016 end.

In terms of geography, North America, being the advanced market, characterized by early adopters of PRP based therapies. The market in North America is estimated to increase by 11.4% in 2016 to reach very close to US$ 120 Mn. Growth of the market in this region is supported by increasing number of cosmetic and orthopaedic surgeries. Moreover, the region is home to some of the most prominent players operating in the PRP market and hence awareness among patients is also high. Awareness among healthcare community as well as patients is also anticipated to fuel the growth of in North American market.

Adoption of PRP therapy in Asia Pacific is growing at a brisk pace, fuelled by the region’s status as an epicentre of medical tourism. The region has a high geriatric population, and adoption of PRP therapy has witnessed a surge in the recent past. The APAC plasma therapy market is anticipated to increase at a year-on-year growth rate of 16.1% in 2016 to reach US$ 40.5 Mn in revenues.

Speak To Analyst@ http://www.futuremarketinsights.com/askus/rep-gb-1722

Key players operating in the global platelet rich plasma market are Harvest Technologies Corp., Biomet, Inc., Arthrex, Inc. and Arteriocyte Medical Systems, Inc. Dr. PRP America, Cesca Therapeutics, Inc., and Regen Lab SA.

Long-term Outlook: The global platelet rich plasma market is projected to increase at a CAGR of over 12.0% during the forecast period from 2016-2026. North America is forecast to dominate the global market throughout the forecast period, whereas orthopaedic surgery will be the largest application segment.

Saudi Arabia Pharmaceutical Market: Retail Pharmacies will Continue to Account For 80% Market Share

The significant rise in lifestyle-related diseases and the developments in healthcare infrastructure are expected to influence the demand for pharmaceuticals in Saudi Arabia. In 2016, the Saudi Arabia pharmaceutical market is anticipated to procure value worth US$ 5,209.5 Mn at a y-o-y growth of 6.0 % over 2015. The mounting demand for branded drug products will continue to incite the growth of the Saudi Arabian pharmaceutical market in 2016.

The demand for pharmaceuticals in Saudi Arabia is expected to register substantial growth owing to the increasing penetration of health insurance companies and the rising incidence rate of non-communicable diseases. Furthermore, the exceptional rise in the per capita income of Saudi Arabia is also expected to foster the demand for branded pharmaceutical drugs. Another key factor driving the growth of the pharmaceutical market in Saudi Arabia is the country’s strategic move to allow 100% FDI in the pharmaceuticals sector. Although, the shortage of profound indigenous research capacity in the pharmaceutical industry and the delayed registration of drug and medicine patents is expected to limit the expansion of the market in 2016 and beyond.

Based on the product type, the pharmaceutical market in Saudi Arabia is expected to witness an upsurge in the prescription-type branded drug products. In terms of market value, the branded drugs are estimated to reach US$ 2,760.8 Mn by 2016-end. The demand for generic drugs is projected to secure steady growth, attributing to the insisting promotion of generic drug adoption by healthcare insurance providers.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gc-1733

On the basis of the diseases, the pharmaceutical drugs used for treatment of cardiovascular diseases will continue exhibiting robust growth in 2016. The demand for cardiovascular medications will continue to surge due to the prominence of circulatory disorders in Saudi Arabia. Additionally, the rising prevalence of disorders related to body sugar levels is expected to make diabetes a rapidly growing disease-based sub-segment in the Saudi Arabia pharmaceutical market.

The pharmaceutical market in Saudi Arabia is also segmented on the basis of distribution channel, where retail pharmacies will continue to account for 80% market share compared to hospital pharmacies. The westernised modernisation of retail pharmacies in Saudi Arabia has led to the availability of a wide range drugs and medicinal products, thereby attaining a considerable growth in the retail pharmacy sub-segment in 2016 and further.

The rising resource potential in Saudi Arabia is projected to positively reform the production environment for pharmaceutical manufacturers. In order to expand the market’s size, structuring alliances with well-established native companies is predicted to be a key strategy for global pharmaceutical leaders. The key players in the Saudi Arabia pharmaceutical market include Novartis AG, SPIMACO, Pfizer Inc., and Glaxosmithkline plc. Jamjoom Pharma, and Tabuk Pharmaceutical Manufacturing Co. among others.

Speak To Analyst@ http://www.futuremarketinsights.com/askus/rep-gc-1733

Long-term Outlook: The Saudi Arabia pharmaceutical market is expected to expand at a CAGR of 9.0% over the forecast period 2016-2026. In terms of market value, the pharmaceutical market in Saudi Arabia is estimated to be worth US$ 12,281.4 Mn by the end of forecast period.